Physician profile
John Rapacz
NPI 1508858853
$3,809.72
in general payments reported to CMS, 2019-2025
27 companies · $1,059 in 2025
The $1,059 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $503 · 2023: $1,138 · 2024: $1,110 · 2025: $1,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,307.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.64 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $535.86 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $380.81 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $331.71 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $297.92 | 2022-2025 | |
| Glaxosmithkline, LLC. | $212.00 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.98 | 2022-2025 | Jardiance |
| Amgen INC. | $163.87 | 2023-2025 | Otezla, Repatha, Otezla |
| Abbott Laboratories | $129.91 | 2023-2025 | Freestyle Libre 3 |
| Pfizer INC. | $92.71 | 2023-2025 | |
| Antares Pharma, INC. | $79.96 | 2023-2025 | Xyosted, Tlando, Nocdurna |
| Dexcom, INC. | $78.45 | 2022-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $71.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.96 | 2023-2025 | Xifaxan |
| Almatica Pharma LLC | $48.15 | 2023-2024 | Loreev Xr, Gralise, Sertraline Hcl |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $43.76 | 2024 | Aplenzin, Wellbutrin |
| Edwards Lifesciences Corporation | $41.61 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.52 | 2022-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $33.44 | 2023 | Quviviq |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.30 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.90 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $20.63 | 2022 | |
| Sumitomo Pharma America, INC. | $19.99 | 2024 | Gemtesa |
| Astellas Pharma US INC | $18.35 | 2022 | |
| Teleflex LLC | $17.57 | 2022 | |
| Paratek Pharmaceuticals, INC. | $13.48 | 2024 | Nuzyra |
| Ultragenyx Pharmaceutical INC. | $13.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rapacz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.